QLS12010 in Participants With Moderate-to-severe Rheumatoid Arthritis

Summary

The objective of this randomized, double-blind, placebo-controlled phase II clinical trial is to investigate the safety and efficacy of QLS12010 in subjects with moderate-to-severe rheumatoid arthritis.The main questions it aims to answer are: • Efficacy and safety of QLS12010 in participants with rheumatoid arthritis. Participants will be randomly allocated to four treatment groups at a 1:1:1:1 ratio to compare the efficacy and safety of different dosages of QLS12010 Capsules against the placebo.

Timeline

Start

2026-03-05

Primary completion

2028-03-05

Completion

2028-06-05

Drugs

Indications